Navigation Links
Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
Date:12/6/2007

SAN DIEGO, CA, Dec. 6 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the Company has completed enrollment and initiated dosing of the second cohort of patients in its Phase 1 dose escalation trial examining the safety of its lead candidate, HspE7, in patients with cervical dysplasia, a precursor to cervical cancer. HspE7 is an investigational therapeutic vaccine targeting human papillomavirus (HPV)-related diseases. Patients in this cohort have received the first of three immunizations of 500 mcg of HspE7 with 500 mcg of adjuvant.

In addition to safety and tolerability assessment, Nventa will also collect immunological data from these patients at the end of each cohort that may provide an early indication of potential efficacy of the compound. All patients will be typed for class I and II human leukocyte antigen (HLA) subtypes, and will be evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

"We are very pleased that patient enrollment in this study has accelerated," said Peter Emtage, Ph.D., Vice President of Research and Development at Nventa. "We believe this is in recognition of the enthusiasm and support from participating clinical trial sites. With the majority of all study participants in the queue, we expect continued progress with enrollment in this Phase 1 study."

Affiliations and investigators in this trial currently include the Montefiore Medical Center; William D. Kolton, M.D. of San Diego, California; Linda Roman, M.D. of the University of Southern California (USC); Michael L. Twede, M.D. of the Salt Lake Women's Center in Sandy, Utah; and Mark T. Saunders, M.D. at the Mt. Timpanogos Women's Healthcare/Physician's Research in Pleasant Grove, Utah.

The trial is expected to dose up to 5 cohorts totaling twenty-four patients. Four cohorts will be administered 500 mcg of HspE7 and doses of 50, 500, 1,000, or 2,000 mcg of adjuvant containi
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... rare diseases that afflict skeletal growth through abnormalities ... the fetal stage and is caused by genetic ... growth factor receptor 3 (FGFR3) has been associated ... (TD), a skeletal dysplasia that cause serious respiratory ... achondroplasia (ACH), which causes stunted growth and other ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Directors,of Eli Lilly and Company (NYSE: LLY ) ... December 1, 2008. Oberhelman, 55, currently serves as,a group ... Caterpillar,s,executive office. As a member of Lilly,s board, Oberhelman ... committee. He will stand for,election by Lilly shareholders at ...
... KANNAPOLIS, N.C., Oct. 20 Academia, science, industry,and ... at 10,AM at the Dedication and Open House ... the UNC Nutrition Research Building and the NC,State ... Nutrition,Research Building is home to NC A&T University, ...
... Recruitment, and Employment Branding joins Pierpoint International as Global VP of ... ... (PRWEB) October 20, 2008 -- Pierpoint International is pleased to announce ... and Diversity. Mr. Cantu, most recently served as AVP of Staffing ...
Cached Biology Technology:Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3Campus Celebrates Historic Milestone 2Campus Celebrates Historic Milestone 3Campus Celebrates Historic Milestone 4Campus Celebrates Historic Milestone 5Robert Cantu Appointed Vice President of Pierpoint International 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... Colo., USA Miranda, a small, icy moon of ... enigmatic bodies in the solar system. Despite its relatively ... of intense resurfacing that resulted in the formation of ... polygonal-shaped regions called coronae. , These coronae are ... at least 200 km across. Arden corona, the largest, ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... MIAMI March 10, 2011 -- Scientists from the University ... were part of a national research team to find two ... Horizon oil spill. In a study published in this week,s ... offers new insight into the mechanism by which the crude ...
... of California, San Francisco (UCSF) has developed a new ... but untreatable and incurable neurodegenerative disease. The disease, frontotemporal ... dementia before age 65, after Alzheimer,s disease. Based ... work explains in part why the brain deteriorates in ...
... New Orleans, LA LSU oncologist Vince D. ... article reporting two chemotherapy drugs now indicated for second ... cancer are remarkably effective in treating a certain subset ... of Medicine at LSU Health Sciences Center New Orleans ...
Cached Biology News:New study reveals aerosol plumes downwind of the Deepwater Horizon oil spill 2UCSF report describes new model for neurodegeneration 2UCSF report describes new model for neurodegeneration 3Study shows new treatment strategy effective for certain lung cancers 2
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
... collects data from balances and scales with RS232 ... other program. If you can type the weight ... collection process Simple to use parser extracts ... , Add user information , Collect data at ...
... collection and automation that is controlled from within ... , Pre-configured library of interfaces for balances, ... be added and configured by the user ... one spreadsheet , Allows for multi-tasking ...
...
Biology Products: